Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once versus twice intracoronary Wharton's jelly mesenchymal stem cell injection after myocardial infarction
IRCT20201116049408N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Aug 2020
- Countries
- 1
01
Overview
Phase 3, single-blind trial of allogeneic Wharton's jelly-derived mesenchymal stem cells in myocardial infarction (MI) (3 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Effect of stem cell injection on echocardiographic findings. Started Aug 2020; status: completed.
02
Drugs
allogeneic Wharton's jelly-derived mesenchymal stem cells
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT20201116049408N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201116049408N1.